Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-10-03
1999-11-09
Degen, Nancy J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 44, A61K 3170
Patent
active
059814870
ABSTRACT:
The present invention relates, in general, to vascular smooth muscle proliferation and, in particular, to a method of inhibiting arterial and venous smooth muscle proliferation resulting, for example, from arterial injury or vein grafting. The invention also relates to an expression construct encoding a G.beta..gamma. inhibitor suitable for use in such a method.
REFERENCES:
patent: 5624936 (1997-04-01), DeSolms
Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science 270:404-410 (1995).
Marshall, "Less Hype, More Biology Needed for Gene Therapy", Science 270:1751 (1995).
Coghlan, "Gene dream fades away", New Scientist 148:14-15 (1995).
Gunsburg et al, "Virus vector design in gene therapy", Molecular Medicine Today pp. 410-417 (1995).
Froecking et al, "Powerful and versatile enhancer-promoter unit for mammalian expression vectors", Gene 45:101-105 (1986).
Lee et al, "Cardiac and Pulmonary Replacement", J. Thoracic Cardiovascular Surgery 111(1):246-252 (1996).
Fuller et al, "Genetic Engineering of Cardiac Muscle Cells: In Vitro and In Vivo", Genetic Engineering 16:17-27 (1994).
Luckow et al, "CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements", Nucleic Acids Research 15(13):5490 (1987).
Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Predicition, K. Merz, Jr. and S. Le Grand, Editors, Birkhauser Bost Inc., pp.491-495 (1994).
Dillon, "Regulating gene expression in gene therapy", TIBTECH 11:167-173 (1993).
Rigby, "Gene therapy: a long and winding road",Current Opinion in Genetics and Development 5:397-398 (1995).
Orkin et al, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", pp. 1-50, Dec. 7, 1995.
Akhter et al, "Restoration of .beta.-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer", Proc. Natl. Acad. Sci. USA 94: 1-6 (1997).
Lilly et al, "Intracoronary Administration Of Adenovirus For Gene Transfer Into Adult Rabbit Myocardium", Surgical Forum, pp. 279-281 (19s.
Drazner et al, "Potentiation of .beta.-Adrenergic Signaling by Adenoviral-mediated Gene Transfer in Adult Rabbit Ventricular Myocytes", J. Clin. Invest. 99(2):288-296 (1997).
Hawes et al, "Determination of the G.beta..gamma.-binding Domain of Phosducin", The Journal of Biological Chemistry 269(47):29825-29830 (1994).
Kobilka et al.. "cDNA for the human .beta..sub.2 -adrenergic receptor: A protein with multiple...," Proc. Natl. Acad. Sci. USA, vol. 84, Jan. 1987, pp. 46-50.
Kass-Eisler et al.. "Quantitative determination of adenovirus-mediated gene delivery . . ., " Proc. Natl. Acad. Sci. USA, vol. 90, Dec. 1993, pp. 11498-11502.
Stratford-Perricaudet et al., "Widespread Long-term Gene Transfer to Mouse Skeletal . . . , " J. Clin. Invest.. Vol. 90, Aug. 1992, pp. 626-630.
Guzman et al., "Efficient Gene Transfer into Myocardium by Direct Injection of Adenovirus Vectors," Circulation Research, vol. 73, 1993, pp. 1202-1207.
Bertin et al., "Specific atrial overexpression of G protein coupled human .beta..sub.1 adrenoceptors . . . ," Cardiovascular Research. Vol. 27. 1993, pp. 1606-1612.
Metzger et al. "Specific troponin C reduces contractile sensitivity to acidosis on cardiac . . . ," Proc. Natl. Acad. Sci. USA, vol. 90. Oct. 1993, pp. 9036-9040.
Ren et al., "Constitutively Active Mutants of the .alpha..sub.2 -Adrenergic Receptor," The Journal of Biological Chemistry, vol. 268, No. 22, Aug. 5, 1993, pp. 16483-16487.
Pauletto et al., "Propranolol-induced changes in ventricular isomyosin composition in the rat," American Heart Journal. Vol. 109, Jun. 1985. pp. 1269-1273.
Bristow et al., "Decreased Catecholamine Sensitivity and .beta.-Adrenergic-Receptor . . . , " The New England Journal of Medicine, vol. 307. No. 4. Jul. 22, 1982, pp. 205-211.
Bristow et al., .beta.-Adrenergic Function in Heart Muscle Disease and Heart Failure, J. Mol. Cell. Cardiol. 17 (Supp. 2), 1985, pp. 41-52.
Bristow et al., ".beta.-Adrenergic Pathways in Nonfailing and Failing Human Ventricular Myocardium," Circulation, vol. 82 (Suppl. I), 1990, pp. I-12-I-25.
Fowler et. al., "Assessment of the .beta.-adrenergic receptor pathway in the intact failing human heart : . . . , " Circulation, vol.74, No. 6, Dec. 1986, pp. 1290-1302.
Ungerer et al., "Altered Expression of .beta.-Adrenergic Receptor Kinase and .beta..sub.1 -Adrenergic . . . ," Circulation, vol. 87, 1993, pp. 454-463.
Benovic et al., ".beta.-Adrenergic Receptor Kinase: Primary Structure Delineates a Multigene Family," Science. Vol. 246, Oct. 13, 1989, pp. 235-240.
Hausdorff et al., "Turning off the signal: desensitization of .beta.-adrenergic receptor function." The FASEB Journal. Vol. 4, Aug. 1990, pp. 2881-2889.
Lohse et al., "Multiple Pathways of Rapid .beta..sub.2 -Adrenergic Receptor Desensitization." The Journal of Biological Chemistry. Vol. 265, No. 6. Feb. 25, 1990, pp. 3202-3209.
Inglese et al., "Structure and Mechanism of the G Protein-coupled Receptor Kinases." The Journal of Biological Chemistry, Vol. 268, No. 32, Nov. 15, 1993, pp. 23735-23738.
Ng et al., "Cardiac Myosin Heavy Chain mRNA Expression and Myocardial Function in the Mouse Heart, " Circulation Research. Vol. 68, No. 6, Jun. 1991, pp. 1742-1750.
Medford et al., "Molecular Mechanisms Regulating VCAM-1. ICAM-1 and E-Selection Gene Expression in Human Aortic Smooth Muscle Cells". Clinical Research, vol. 41, No. 2, 1993, p. 145A.
Pitcher et al., "Role of .beta..rho. Subunits of G Proteins in Targeting the .beta.-Adrenergic...". Science, vol. 257, Aug. 28, 1992, pp. 1264-1267.
Yatani et al., "A G Protein Directly Regulates Mammalian Cardiac Calcium Channels," Science, vol. 238, Nov. 1987, pp. 1288-1292.
Laugwitz et al, "Characterization and inhibition of .beta.-adrenergic receptor kinase in intact myocytes", Cardiovascular Research 35:324-333 (1997).
Xu et al, "The N terminus of phosducin is involved in binding of .beta..gamma. subunits of G protein", Proc. Natl. Acad. Sci. USA 92:2086-2090 (1995).
Koch et al, "Cellular Expression of the Carboxyl Terminus of a G Protein-coupled Receptor Kinase Attenuates G.beta..gamma.-mediated Signaling", The Journal of Biological Chemistry 269(8):6193-6197 (1994).
Inglese et al. (1994) Functionally active targeting domain of the beta-adrenergic receptor kinase: an inhibitor of Gbetagamma-mediated stimulation of type II adenylyl cyclase. Proc. Natl. Acad. Sci. USA 91:3637-3641. Apr. 1994.
Irani et al. (1994) Ras proteins regulate multiple mitogenic pathways in A10 vascular smooth muscle cells. Biochem. Biophys. Res. Comm. 202:1252-1258. Aug. 1994.
Koch et al., "The Binding Site for the .beta..tau. Subunits of Heterotrimeric G Proteins . . . ," The Journal of Biological Chemistry. Vol. 268, No. 11, Apr. 15, 1993, pp. 8256-8260.
Hagen Per-Otto
Koch Walter J.
Lefkowitz Robert J.
Degen Nancy J.
Duke University
Schwartzman Robert
LandOfFree
Method of inhibiting smooth muscle cell proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting smooth muscle cell proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting smooth muscle cell proliferation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1455997